JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS) Save

Know-it-now

• POTS diagnosis is clinical and physiological diagnosis - a 10-minute active stand test (HR rise ≥30 bpm without orthostatic hypotension
• Comorbidity is common: nearly all patients have overlapping conditions—hypermobility spectrum disorders/hEDS (25%), fibromyalgia (20%), and ME/CFS (21%)—syndromes that already populate rheumatology panels.
• Evidence-based nonpharmacologic therapy is first-line: salt/fluid loading, compression garments, and supervised recumbent-to-upright exercise should be tried before medications.
• Many meds can provoke POTS: SNRIs, stimulants, and spironolactone (all common in rheumatology practice for pain, fatigue, or acne/PCOS)
• Prognosis is guarded but not malignant: no excess mortality, but long-term surveys show only 2% symptom resolution at a median of 17–23 years post-diagnosis, with 70% reporting income loss—counsel patients accordingly.

Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance. Diagnosis requires a sustained heart rate rise of ≥30 beats/min (≥40 beats/min in ages 12–19) within 10 minutes of standing or tilt, without orthostatic hypotension (systolic BP drop ≥20 mm Hg or diastolic ≥10 mm Hg), measures that can easily be performed in an outpatient clinic. Diagnosis is confirmed by ≥3 months of orthostatic symptoms after excluding mimics (thyroid disease, anemia, dehydration, cardiac arrhythmia, medication effects).

The primary pathophysiology stems from central hypovolemia from venous pooling (splanchnic, pelvic, lower-extremity), compensated by baroreflex-driven sympathetic activation and sinus tachycardia. Contributing mechanisms include patchy sympathetic vasomotor denervation (demonstrated by reduced norepinephrine spillover and blunted muscle sympathetic nerve activity), a renin-angiotensin-aldosterone "paradox" (inappropriately low aldosterone despite hypovolemia), physical deconditioning with cardiac atrophy, and postinfectious immune-mediated autonomic injury—30%–40% of cases begin within weeks of an infection (SARS-CoV-2, EBV, influenza). Autoantibodies against adrenergic and other G-protein-coupled receptors have been identified in small cohorts, though causality is unproven.

The comorbidity burden is high: 83% of patients report ≥1 comorbid condition, including chronic migraine (40%), irritable bowel syndrome (30%), hypermobile Ehlers-Danlos syndrome (25%), ME/CFS (21%), fibromyalgia (20%), and mast cell activation syndrome (9%). POTS is reported in 30%–80% of long-COVID cohorts.

A stepwise approach to treatment is recommended. First-line nonpharmacologic measures include 10–12 g/day sodium, 2–3 L/day water, lower-body/abdominal compression garments, and structured recumbent-to-upright supervised aerobic exercise (the only measures with randomized trial support—e.g., compression reduced orthostatic HR rise from 39 to 23 beats/min in one crossover trial; a 12-week semi-supervised exercise program improved peak oxygen uptake by 3.4 mL/kg/min vs. placebo). Pharmacotherapy is symptom-guided and entirely off-label: heart-rate lowering (propranolol, ivabradine), vasoconstriction (midodrine), volume expansion (fludrocortisone, desmopressin), and central sympatholytics (clonidine, guanfacine, methyldopa) for hyperadrenergic features. Clinicians should proactively deprescribe agents that worsen POTS—stimulants, SNRIs, spironolactone, α1-blockers, and vasodilators.

Surprisingly, this review failed to note the association between POTS and fibromyalgia - a common clinical overlap. 

The review sparingly notes that fibromyalgia is seen in 20% of POTS patients.  FM and POTS are bidirectional bedfellows and frequently comorbid. Both disorders commonly coassociate with chronic fatigue syndrome, migraine, functional GI/gut-brain disorders, joint hypermobility/Ehlers-Danlos, and anxiety.  Both involve autonomic dysfunction and central sensitization. Commonly autonomic symptoms (orthostatic intolerance, palpitations, fatigue, cognitive fog) are near-universal complaints in FM clinics, and many rheumatologists would estimate the overlap is considerably higher than 20% in practice. Other literature bears this out: a JACC focus seminar on POTS lists fibromyalgia among the most frequent nonorthostatic comorbidities, alongside chronic fatigue (up to 48%) and migraine, and proposes that POTS, ME/CFS, and FM may represent overlapping points on a shared dysautonomia-driven spectrum rather than distinct diseases. Chronic fatigue has been reported in up to 48% of POTS patients, reflecting the broader fatigue/pain comorbidity cluster that overlaps with FM. Central sensitization syndrome itself was found in 86.6% of POTS patients, framing FM as one manifestation of a much broader central-sensitization burden in this population. 

Practically, rheumatologists should consider screening FM patients with orthostatic or autonomic symptoms using a simple in-office active stand test, and conversely should not assume that tachycardia, presyncope, or exertional intolerance in an FM patient is "just fibromyalgia", it may be treatable POTS.